Main description:

This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies.

Contents:

Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma.- Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma.- Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance.- Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance.- Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma.- Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma.- Sorafenib and Clinical Patterns of Resistance in hepatocellular carcinoma.- Overcoming Treatment Resistance in Hepatocellular Carcinoma: regorafenib and lessons from other malignancies.